H-Gemcitabine: A New Gemcitabine Prodrug for Treating Cancer
Bioconjugate Chemistry2012Vol. 24(1), pp. 4–8
Citations Over Time
Madhuri Dasari, Abhinav P. Acharya, Dongin Kim, Seungjun Lee, Sungmun Lee, Jeanne M. Rhea, Ross J. Molinaro, Niren Murthy
Abstract
In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.
Related Papers
- → Gemcitabine in non-small cell lung cancer(1995)12 cited
- → Gemcitabine in the treatment of ovarian cancer(1999)5 cited
- → Gemcitabine treatment enhances the activity of deoxycytidine kinase in periferial lymphocytes of patients with pancreatic cancer(2004)
- → Supplementary Figure 1 from The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase(2023)